Can a female patient taking methotrexate and adalimumab (Hadlima) safely be prescribed metronidazole?

Can Metronidazole Be Safely Prescribed with Methotrexate and Adalimumab?

Yes, metronidazole can be prescribed to a patient taking methotrexate and adalimumab (Hadlima), as there are no documented contraindications or significant drug interactions between these medications.

Drug Interaction Analysis

Metronidazole with Methotrexate

The FDA label for methotrexate lists specific contraindications including pregnancy, nursing, alcoholism, chronic liver disease, immunodeficiency, and blood dyscrasias, but does not list metronidazole as a contraindicated medication 1. The guidelines note that "relative contraindications include concomitant use of sulfa drugs and acitretin" 2, but metronidazole is neither a sulfa drug nor listed among problematic combinations.

Metronidazole with Adalimumab (Hadlima)

The Hadlima FDA label explicitly addresses drug interactions and does not mention metronidazole 3. The documented interactions for adalimumab include:

• Methotrexate: Safe to use together (no dose adjustment needed) 3
• Other biologics: Not recommended (anakinra, abatacept, other TNF blockers)
• Live vaccines: Avoid
• CYP450 substrates: Monitor narrow therapeutic index drugs (warfarin, cyclosporine, theophylline)

Metronidazole does not fall into any of these problematic categories.

Important Clinical Considerations

Infection Risk Monitoring

While metronidazole itself is safe to prescribe, the reason for prescribing it matters significantly. Both methotrexate and adalimumab increase infection risk:

• Adalimumab carries a two-fold increased risk of serious infections 4
• The combination of TNF blockers with methotrexate has been associated with increased serious infections in clinical studies 3
• Tuberculosis reactivation and atypical/deep fungal infections are notable concerns with adalimumab 4

If metronidazole is being prescribed for a suspected serious infection (such as intra-abdominal infection, aspiration pneumonia, or anaerobic infection), ensure:

• The infection is adequately evaluated and not an opportunistic infection mimicking a common bacterial process
• Consider whether immunosuppression should be temporarily held depending on infection severity
• Rule out Pneumocystis jirovecii pneumonia (PCP), which can occur with adalimumab and may be misdiagnosed 5

Hepatotoxicity Monitoring

Both methotrexate and metronidazole have hepatotoxic potential:

• Methotrexate requires liver function monitoring every 3-6 months 2
• Patients with risk factors for hepatotoxicity (including chronic liver disease) should not receive methotrexate 2, 1
• While metronidazole can cause hepatotoxicity, short courses are generally safe if baseline liver function is acceptable

Ensure liver function tests are current before prescribing metronidazole, particularly if the patient has any hepatotoxicity risk factors.

Practical Prescribing Algorithm

1. Verify indication: Confirm metronidazole is appropriate for the suspected infection
2. Check recent labs: Review liver function tests (should be within 3-6 months per methotrexate monitoring guidelines 2)
3. Assess infection severity: If serious infection suspected, consider infectious disease consultation and potential temporary hold of immunosuppression
4. Prescribe standard metronidazole dosing: No dose adjustment needed for the drug combination itself
5. Monitor clinically: Watch for worsening symptoms that might suggest opportunistic infection rather than typical bacterial infection

Common Pitfalls to Avoid

• Do not assume all pulmonary infections are bacterial: PCP can mimic drug-induced pneumonitis or bacterial pneumonia in patients on adalimumab and methotrexate 5
• Do not overlook alcohol use: Metronidazole causes disulfiram-like reactions with alcohol, and patients on methotrexate should already be limiting alcohol due to hepatotoxicity risk 2
• Do not prescribe if liver function is significantly abnormal: Both drugs have hepatotoxic potential